Live Breaking News & Updates on Akeso inc

Summit Therapeutics (NASDAQ:SMMT) versus Alimera Sciences (NASDAQ:ALIM) Financial Survey

Summit Therapeutics (NASDAQ:SMMT) versus Alimera Sciences (NASDAQ:ALIM) Financial Survey
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Alpharetta , Georgia , United-states , Cambridge , Cambridgeshire , Massachusetts , Summit-therapeutics-inc , Alimera-sciences-inc , Akeso-inc , Alimera-sciences

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC

Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states , Australia , China , Hong-kong , Canada , Japan , Akeso-inc , Prnewswire-akeso-inc , Summit-therapeutics , Main-board , Stock-exchange

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2023

Promising Updated Phase II Data Presented at ASCO 2023 for Ivonescimab

First US Patient Treated in Ivonescimab Phase III Clinical Trial with the First Patient in Ivonescimab s Second Phase III.

United-kingdom , China , Canada , Japan , Australia , Menlo-park , California , United-states , American , Chinese , Team-summit

The eClinical Medicine of Lancet Published Phase 2 Results of Ivonescimab for the Treatment of NSCLC

/PRNewswire/ Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing.

United-states , China , Li-zhang , Zhejiang , Akeso-inc , Sun-yat-sen-university-cancer-center , Clinical-medicine , Professor-li-zhang , Sun-yat-sen-university-cancer , New-drug-application , Summit-therapeutics

Akeso Inc. Published 2023 Interim Results Positive Profit Alert

/PRNewswire/ Akeso Inc. ("Akeso", the "Company"; 9926.HK), a commercial-stage biopharmaceutical company focused on developing and commercializing.

Canada , China , Japan , Akeso-inc , Company-for-the-reporting-period , Prnewswire-akeso-inc , Reporting-period , Summit-therapeutics , Takeso , Nc ,

Unleashing the Potential: PD-1/PD-L1 Inhibitors Market Soars to $123.3 Billion by 2033, Embracing a

The PD-1/PD-L1 Inhibitors Market Size is anticipated to be valued at US$ 49.5 billion in 2023, rising to US$ 123.3 billion by 2033. Over the forecast period, the market is expected to grow at a substantial CAGR of 9.6%.Because of the growing worldwide cancer burden, the usage of PD-1 and PD-L1 inhibitors, which are.

China , United-states , India , New-york , Tianqing , Zhejiang , Tamil-nadu , Delaware , Eli-lilly , Greater-new-york-chamber , Market-insights-inc , Bristol-myers-squibb-co

Promising 2-year updated data from cadonilimab presented at 2023 ASCO highlighting promising efficacy in PD-L1-negative patients

/PRNewswire/ Akeso, Inc. (9926.HK) ("Akeso") released two-year updated data from a Phase Ib/II clinical study of cadonilimab – a first-in-class PD-1/CTLA-4.

United-states , China , Chinese , American , Remarkable , Prnewswire-akeso-inc , American-society-of-clinical-oncology , Akeso-inc , Clinical-oncology , Takeso , Nc

Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023

Data Supporting Summit’s Planned Phase III Trial for First-line Metastatic Squamous NSCLC Patients on Display

Phase II ORR of 67% with a mDOR of 15 months in 1L SQ-NSCLC Patients

. | June 4, 2023

Li-zhang , Zhejiang , China , Yu-zhang , Canada , California , United-states , United-kingdom , Li-zhuang , Henan , Weifeng , Shaanxi

NMPA accepted Akeso's ebronucimab (PCSK9) marketing application in two cardiovascular indications

/PRNewswire/ Akeso Inc. (9926. HK, "Akeso") announced today that China s National Medical Products Administration (NMPA) has accepted its New Drug.

China , Ad-pharmaceuticals , Akeso-inc , China-national-medical-products-administration , National-medical-products-administration , New-drug-application , Takeso , Nc ,

Ivonescimab Updated Data to be Featured at ASCO 2023

Summit Therapeutics is Currently Enrolling in a Phase III Study with Additional Phase III Study Planned for Third Quarter 2023 for Ivonescimab

. | June 1, 2023

Li-zhang , Zhejiang , China , Australia , United-kingdom , Yu-zhang , Weifeng , Shaanxi , Menlo-park , California , United-states , Ming-zhou